Cincinnati-based AtriCure, a surgical-devicemaker, said it received Food and Drug Administration approval of its Isolator Synergy Bipolar Ablation System for removal of soft tissue. The company said the device isnt yet cleared for removal of cardiac tissue. AtriCure said the device, which incorporates two pulsing pairs of electrodes in the jaws of the clamp to remove thicker, diseased tissue, is available for open surgical procedures. The company said it plans a minimally invasive version this summer.
Read more (registration may be required).